Full-Time

Financial Analyst

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$70k - $80kAnnually

+ Annual Bonus + Equity

Junior

New York, NY, USA

On-site requirement of at least three days per week; unable to consider candidates looking for fully remote roles.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Financial analysis
Data Analysis
Excel/Numbers/Sheets

You match the following Axsome Therapeutics Inc's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s Degree in Accounting, Finance, Economics or Business Administration
  • At least 1 year of experience in a Finance or Accounting role
  • Intermediate or advanced excel skills required
  • Ability to work on-site Monday, Tuesday, and Thursday. We are unable to consider candidates who are looking for fully remote role
Responsibilities
  • Ensure complete and accurate accounts receivable (AR), deduction validation, and return reconciliation functions via high level analytics and other related activities
  • Monitor and maintain system of record for all accounts receivable transactions including cash collections, distributor deductions, credits, etc.
  • Research and resolve customer deductions; coordinate with business partners to resolve contested items, recommend appropriate action for item handling. Either issue credit or contact customer to collect unauthorized deductions
  • Prepare, verify and complete data entry of pricing, promotional, return and or other credit memo documents
  • Responsible for ensuring the Accounts Receivable and cash collections processes operate in a well controlled environment in accordance with Sarbanes Oxley standards including the implementation and execution of internal controls
  • Execute and perform all Accounts Receivable activities downstream of basic cash application and communicate problems/opportunities in a timely manner
  • Follow up on overdue items and educate leadership on any trends impacting the sales collection process
  • Close communication with external partners and customers to fill in gaps in data and affect outcome on any corrective actions needed
  • Collaborate with internal stakeholders within Market Access and Trade/Distribution
  • Prepare reports and dashboards to educate Axsome leadership on trade and distribution finance related topics
  • Gross to net calculations and analytics
  • Gross to net administration of third party claims including validation support, and accuracy of the general ledger
  • Responsibility for the execution of select Gross to net internal controls
  • Support the inventory process through close collaboration with Supply Chain
Desired Qualifications
  • Possess a problem-solving mindset with demonstrated “lean-forward” approach and the ability to think critically
  • Strong analytical and research skills
  • Knowledge of Sarbanes-Oxley a plus
  • Strong planning and organization skills, attention to detail, execution, and follow-through
  • Excellent oral, written and presentation skills
  • Ability to influence decision makers and educate variety of internal audiences on complex concepts
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that acts as an NMDA receptor antagonist, blocking brain receptors involved in mood regulation. This drug has shown promise in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS treatment and aims to improve patient outcomes through rigorous clinical trials and regulatory approvals. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these disorders.

Company Size

201-500

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
  • Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
  • Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

What critics are saying

  • Increased competition from companies like Compass Pathways in the CNS market.
  • Potential delays in AXS-07 launch amid growing market anticipation.
  • Departure of key personnel like Lori Englebert may impact strategic direction.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders with limited current treatment options.
  • AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 4th, 2024
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 2nd, 2024
PDT Partners LLC Makes New $1.05 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

PDT Partners LLC makes new $1.05 million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Nov 29th, 2024
FORA Capital LLC Makes New $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

FORA Capital LLC makes new $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).